Ginkgo Bioworks/$DNA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Ginkgo Bioworks

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Ticker

$DNA
Sector

Primary listing

NYSE

Industry

Chemicals

Employees

834

ISIN

US37611X2099

Ginkgo Bioworks Metrics

BasicAdvanced
$745M
-
-$8.92
1.29
-

Bulls say / Bears say

Ginkgo Bioworks has expanded its partnerships with major pharmaceutical companies, including Merck and Boehringer Ingelheim, to enhance biologics manufacturing and develop novel therapies, potentially leading to increased revenue streams. (prnewswire.com, prnewswire.com)
The company reported a 27% year-over-year increase in total revenue for Q1 2025, indicating positive financial momentum. (biospace.com)
Ginkgo's strategic acquisitions, such as Patch Biosciences and Reverie Labs, are expected to enhance its capabilities in AI and biopharma, positioning the company for future growth. (prnewswire.com)
Despite revenue growth, Ginkgo Bioworks reported a net loss of $91 million in Q1 2025, highlighting ongoing profitability challenges. (biospace.com)
The company's operating margin remains significantly negative at -236.3%, driven by high R&D and SG&A expenses, indicating financial inefficiencies. (marketbeat.com)
Ginkgo's cash reserves have declined from $1.32 billion in 2022 to $312.4 million in Q1 2025, raising concerns about its financial sustainability. (aipha.io)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DNA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs